These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 14527916

  • 1. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
    Qin W, Zhu W, Wagner-Mann C, Sauter ER.
    Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
    [Abstract] [Full Text] [Related]

  • 2. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
    Qin W, Zhu W, Wagner-Mann C, Folk W, Sauter ER.
    Cancer J; 2003 Oct; 9(4):293-301. PubMed ID: 12967140
    [Abstract] [Full Text] [Related]

  • 3. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 5. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M, Herszènyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F.
    Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
    [Abstract] [Full Text] [Related]

  • 11. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 13. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 01; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 14. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK, Gertz RE, Ivins CM, Kacinski BM.
    Cancer; 1995 Apr 01; 75(7):1627-33. PubMed ID: 8826920
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB.
    J Cancer Res Clin Oncol; 2000 Nov 01; 126(11):641-6. PubMed ID: 11079728
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.